These results not only provide the potential application of PFL as a novel therapeutic agent in sensitizing breast cancer cells to paclitaxel but also highlight the potential role of HER2/β-catenin signaling in the development of paclitaxel resistance in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.